Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients

Table 4 Major cardiovascular and venous thrombotic events at diagnosis or during long-term follow-up in 323 polycythemia vera and 639 essential thrombocthemia patients according to the JAK2^V617F mutation status in the retrospective study of Vannucchi (only major thrombotic events were retrospectively recorded excluding the erythromelalgic and migraine like cerebral ischemic events[20])

Patients	PV n = 323		ET n = 625
JAK2V617 mutation status	Hetero homozygous hetero wild type
No. of patients	219	104	368	237
At diagnosis
Major arterial events	21%	15.4%	21.7%	10.5%
Venous events	2.9%	2.9%	7.9%	4.7%
During 10 yr follow-up (not on aspirin)
Major arterial events	10.1%	12.5%	6.3%	5.8%
Venous events	4.1%	7.7%	6.3%	2.7%
Total during life time follow-up
Major arterial	31.1%	27.9%	28%	16.3%
Venous	10.5%	10.6%	14.2%	7.4%

In 14 homozygous ET patients total major arterial and venous events had occurred in 78.6% and 57.1% respectively. PV: Polycythemia vera; ET: Essential thrombocthemia.